← Back to all trials
Recruiting
NCT07638852
Study of Radiotherapy Combined With Platinum, Adebrelimab and Bevazumab in the Treatment of TNBC-BM.
Conditions: TNBC, Triple Negative Breast Cancer, Brain Metastasases
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 58
Sponsor: Fudan University
Location: Fudan University Shanghai Cancer Center Shanghai Shanghai Municipality
Summary
This is an open-label, prospective, single-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with triple-negative breast cancer and brain metastases.
Eligibility Criteria
Inclusion Criteria:
1. Age ≥18 years and ≤70 years, gender not limited;
2. ECOG score 0-2;
3. Pathologically confirmed HR-negative/HER2-negative breast cancer patients with evidence of local recurrence or metastasis, unsuitable for curative surgical resection or radiotherapy; HR-negative is defined as ER-negative and PR-negative, with positive tumor cells accounting for \
Source: ClinicalTrials.gov (NCT07638852). StuddyBuddy aggregates publicly available trial information.
